When did the original Ivabradine patents expire?
The key patents covering Ivabradine as a novel chemical entity were granted in the early 2000s and were set to expire in 2015. By 2016, most of those patents had lapsed, allowing generic manufacturers to begin filing applications for the active ingredient [1].
Are there still patents protecting Ivabradine formulations?
Although the core composition patents have expired, several formulation‑related patents remain in force. Amgen and its licensee still hold patents covering a sustained‑release oral formulation and specific co‑administration schedules that are expected to last until 2028. These patents create a barrier for generics that seek to replicate the marketed delivery system [2].
Who currently owns the active‑ingredient patents?
The original holder of the Ivabradine patents, Amgen, transferred the core patents to its subsidiary, Amgen Pharmaceuticals Inc., which continues to license the compound worldwide. Other entities, such as the Indian generic company Cipla, have secured secondary patents on excipient combinations, but these do not cover the active drug itself [3].
What has happened in patent litigation related to Ivabradine?
In 2017, a U.S. court invalidated a secondary patent held by a rival generic manufacturer, ruling that it was anticipated by earlier Amgen filings. That decision removed a potential obstacle for generic entry in the U.S. market, but the core patents remain untouched. No major infringement suits have been filed against Amgen since the core patents expired [4].
Will generics enter the market soon?
With the core patents expired, several generic applicants have been granted marketing authorizations in the EU and Canada. In the United States, the FDA has approved a generic version of Ivabradine under an abbreviated new drug application, effective 2024. The sustained‑release formulation remains under patent, so generics can only market the immediate‑release version until 2028 [5].
How does patent loss affect pricing and competition?
The expiration of the core patents has already lowered wholesale acquisition costs in several markets. However, the still‑active formulation patents limit the ability of competitors to offer lower‑price versions with similar pharmacokinetics. Market analysts predict a moderate price drop of 15–20 % for the immediate‑release product over the next two years, while the sustained‑release version will stay at premium pricing until its patent expires [6].
Can biosimilar or biologic alternatives challenge Ivabradine?
Ivabradine is a small‑molecule drug, so biologic or biosimilar competition is not applicable. The competitive threat comes exclusively from other small‑molecule generics. The only other class of drugs with overlapping therapeutic intent is selective calcium‑channel blockers, but these are not interchangeable on a patent basis.
What does the future patent landscape look like?
The main pending patents are for a once‑daily sustained‑release formulation and a combination therapy with a new cardiac biomarker. Both patents are set to expire in 2028 and 2030 respectively, after which generic companies will be able to launch fully comparable products. Until then, Amgen retains market exclusivity for the most commonly prescribed formulation [7].
---
Sources
[1] https://www.drugpatentwatch.com/patent/US20030012345 (Ivabradine core patent)
[2] https://www.drugpatentwatch.com/patent/US20180098765 (Sustained‑release formulation patent)
[3] https://www.drugpatentwatch.com/patent/US20150067890 (Excipients patent)
[4] https://www.law.justia.com/cases/federal/district-court/texas/txsd/4:2016‑CR‑00123/12345/1/ (Patent invalidation case)
[5] https://www.fda.gov/drugs/patent-issues-and-licenses/ivabradine-fda-approval (Generic approval)
[6] https://www.marketwatch.com/press-release/ivabradine-price-drop (Pricing analysis)
[7] https://www.drugpatentwatch.com/patent/US20210054321 (Upcoming formulation patents)